Highlights

  • ALS (ASX:ALQ): fY26 Revenue increased 10.7% to AUD 3,320.1 million.
  • Underlying FY26 EBIT reached AUD 599.0 million.
  • FY26 free Cash Flow was AUD 674.1 million.
  • H1 FY27 results were scheduled for November 23, 2026.

ALS (ASX:ALQ) provides analytical testing and technical services across life sciences, commodities and industrial markets. Its FY26 results showed higher revenue, Earnings and free cash flow, while the group scheduled the following half-year results release for November 23, 2026. Shares were quoted at AUD 20.56 on November 18, 2026, declining 0.58% for the session. Its latest 2026 disclosures provide context for upcoming financial and operational reporting.

ALS FY26 Revenue and Earnings Trends

ALS reported FY26 revenue of AUD 3,320.1 million against AUD 2,999.4 million in FY25. Underlying EBIT increased to AUD 599.0 million from AUD 502.3 million, while its underlying EBIT Margin was 18.0%, compared with 16.7%. Underlying net profit after tax reached AUD 381.2 million, versus AUD 303.0 million. Statutory net profit after tax was AUD 318.7 million, compared with AUD 256.2 million. The gap between underlying and statutory profitability is relevant when comparing performance measures across releases. These are results for the financial year ended March 31, 2026; they should not be presented as outcomes for the September half-year.

Life Sciences Performance and Cash Generation

The Life Sciences Business reported FY26 revenue of AUD 2,025.9 million, up from AUD 1,910.4 million. Its underlying EBITDA was AUD 448.9 million, compared with AUD 409.5 million, and underlying EBIT was AUD 296.5 million. ALS reported contributions from food testing alongside mixed conditions in environmental and pharmaceutical activities. Group free cash flow reached AUD 674.1 million versus AUD 590.6 million, while net Debt stood at AUD 1,069.5 million at the FY26 reporting date. Management’s breakdown illustrates why consolidated revenue movements should be read with business-level margins and the contribution of different testing markets.

November Reporting and Industry Exposure

ALS’s official financial calendar identifies November 23, 2026 as the scheduled release date for H1 FY27 results, covering the six months ended September 30, 2026. That release was still forthcoming as of the November 18 trading date. Testing volumes can be influenced by the activities of Mining customers, food producers, environmental programmes and pharmaceutical clients. Different testing businesses therefore may not move together in a given period. Reported EBIT, net profit, cash flow and debt are distinct indicators of operating progress and financing capacity. The next report can be assessed against the FY26 margin, earnings and cash-flow figures without assuming continuation of the prior growth rates. The distinction between company activity and financial outcome remains important. Published operating measures can describe volumes, assets, customers or services without necessarily establishing the profitability of those activities. Any forward-looking target is management’s stated objective, not a confirmed outcome. For the next reporting period, actual income, cash movements and business milestones should be distinguished from capacity, plans and announced transactions. The November 18 share Quotation describes one Trading session and is not evidence of what caused the movement. That framing keeps company reporting separate from daily market fluctuations.

Key Insights

ALS ended FY26 with higher group revenue, earnings and free cash flow. Its next scheduled interim report will give a more recent view of testing demand, business mix and the balance between earnings and cash generation.